Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerT1-T2-T3
- Development stage
- Preclinical
- Lead developer
- HAL Allergy
- Modality
- Peptides
- Administration
- Topical, Intradermal
01
Overview
AllerT1-T2-T3 is a combination of synthetic peptides, specifically a mix of peptides T1, T2, and T3. These peptides are derived from Bet v 1, the major allergen found in birch pollen. Developed by Anergis, this drug is utilized in clinical settings to assess skin reactivity in individuals who are allergic to birch pollen, serving as a diagnostic tool to elicit an immune response. Its mechanism involves presenting these allergen-derived peptides to the immune system to trigger an allergic reaction, thereby determining the subject's sensitivity.
- Other names
- mix of AllerT1-T2-T3
02
Targets
Bet v 1-specific T-cell receptor
Beyond the preview
Go deeper on AllerT1-T2-T3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerT1-T2-T3.